ChangChun High New Technology Industries operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares ChangChun High New Technology Industries with three other
companies in this sector in China:
Shenzhen Hepalink Pharmaceutical Group Co Ltd
sales of 4.81 billion Chinese Renmimbi [US$688.00 million]
of which 100%
was Pharmaceutical Manufacturing),
Changjiang Runfa Medicine Co Ltd
(4.67 billion Chinese Renmimbi [US$667.88 million]
of which 72%
was Medicine), and
Shandong Xinhua Pharmaceutical Company Limited
(5.21 billion Chinese Renmimbi [US$744.20 million]
of which 49%
During the year ended December of 2018, sales at
ChangChun High New Technology Industries were 5.32 billion Chinese Renmimbi (US$760.60 million).
increase of 31.8%
versus 2017, when the company's sales were 4.04 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at ChangChun High New Technology Industries
(and since 2013, sales have increased a total of 162%).
Sales of Medication saw an increase
38.2% in 2018, from
3.44 billion Chinese Renmimbi to 4.75 billion Chinese Renmimbi.
Not all segments of ChangChun High New Technology Industries experienced an increase in sales in 2018:
sales of Service Industry fell 37.3% to 25.42 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).
ChangChun High New Technology Industries also experienced decreases in sales in
Real Estates (down 5.1% to 606.83 million Chinese Renmimbi)